BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 1069555)

  • 1. Immunotherapy of human malignant melanoma with irradiated tumor cells, oral Bacillus Calmette-Guérin, and levamisole.
    Shibata HR; Jerry LM; Lewis MG; Mansell PW; Capek A; Marquis G
    Ann N Y Acad Sci; 1976; 277(00):355-66. PubMed ID: 1069555
    [No Abstract]   [Full Text] [Related]  

  • 2. Adjuvant immunostimulation in malignant melanoma with oral Bacille Calmette-Guérin.
    MacGregor AB; Falk RE; Landi S; Ambus U; Samuel ES; Langer B
    Can J Surg; 1977 Jan; 20(1):25-30. PubMed ID: 832200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized trial of Bacillus Calmette-Guérin (percutaneous administration) as surgical adjuvant immunotherapy for patients with stage-II melanoma.
    Pinsky CM; Hirshaut Y; Wanebo HJ; Fortner JG; Miké V; Schottenfeld D; Oettgen HF
    Ann N Y Acad Sci; 1976; 277(00):187-94. PubMed ID: 1069548
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunotherapy of malignant melanoma.
    Terry WD
    N Engl J Med; 1980 Nov; 303(20):1174-5. PubMed ID: 6999351
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of administration of BCG, levamisole and irradiated leukemic cells on immune status and remission status in chronic myelogenous leukemia.
    Advani SH; Gulwani B; Ghogale SG; Shetye MR; Gangal SG
    Oncology; 1985; 42(5):275-81. PubMed ID: 3897932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCG as adjuvant immunotherapy for neoplasia.
    Hersh EM; Gutterman JU; Mavligit GM
    Annu Rev Med; 1977; 28():489-515. PubMed ID: 324372
    [No Abstract]   [Full Text] [Related]  

  • 7. Calmette-Guerin bacillus treatment of experimental conjunctival malignant melanoma.
    Rutgard J; Peyman GA; Frenkel M; Saks S
    Arch Ophthalmol; 1977 Dec; 95(12):2214-7. PubMed ID: 588117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring immunotherapy with Bacillus Calmette-Guérin by antibody titer.
    Wile AG; Sparks FC; Morton DL
    Cancer Res; 1977 Jul; 37(7 Pt 1):2251-6. PubMed ID: 324610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer immunotherapy.
    Richman SP; Gutterman JU; Hersh EM
    Can Med Assoc J; 1979 Feb; 120(3):322-4, 329. PubMed ID: 371776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of bacillus Calmette-Guerin immunotherapy on tumor antigen-induced lymphocyte-stimulated protein synthesis in melanoma patients.
    Roth JA; Golub SH; Holmes EC; Morton DL
    Surgery; 1975 Jul; 78(1):66-75. PubMed ID: 1138401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of pulmonary metastases of B16 melanoma with irradiated tumor cells and BCG.
    Tai J; Guclu A; Ghose T; Norvell S
    Cancer Immunol Immunother; 1983; 15(1):47-53. PubMed ID: 6553507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Malignant melanoma.
    Spitler LE
    J Invest Dermatol; 1976 Sep; 67(3):435-41. PubMed ID: 787436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy of human solid tumors with Bacillus Calmette-Guérin: prolongation of disease-free interval and survival in malignant melanoma, breast, and colorectal cancer.
    Gutterman JU; Mavligit GM; Blumenshein G; Burgess MA; McBride CM; Hersh EM
    Ann N Y Acad Sci; 1976; 277(00):135-59. PubMed ID: 1069546
    [No Abstract]   [Full Text] [Related]  

  • 14. Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the National Cancer Institute of Canada Clinical Trials Group.
    Quirt IC; Shelley WE; Pater JL; Bodurtha AJ; McCulloch PB; McPherson TA; Paterson AH; Prentice R; Silver HK; Willan AR
    J Clin Oncol; 1991 May; 9(5):729-35. PubMed ID: 2016615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy of established micrometastases with Bacillus Calmette-Guérin tumor cell vaccine.
    Hanna MG; Peters LC
    Cancer Res; 1978 Jan; 38(1):204-9. PubMed ID: 201374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inconsistent response of B16 melanoma to BCG immunotherapy.
    Kreider JW; Bartlett GL; Purnell DM
    J Natl Cancer Inst; 1976 Apr; 56(4):803-10. PubMed ID: 1255799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined immunotherapy in malignant melanoma. Regression of metastatic lesions in two patients concordant in timing with systemic administration of transfer factor and Bacillus Calmette-Guérin.
    Spitler LE; Levin AS; Wybran J
    Cell Immunol; 1976 Jan; 21(1):1-19. PubMed ID: 764975
    [No Abstract]   [Full Text] [Related]  

  • 18. Adoptive transfer and specific active immunization of patients with malignant melanoma.
    Seigler H; Buckley CE; Sheppard LB; Horne BJ; Shingleton WW
    Ann N Y Acad Sci; 1976; 277(00):522-32. PubMed ID: 1069561
    [No Abstract]   [Full Text] [Related]  

  • 19. Oral bacille Calmette Guérin immunostimulation in malignant melanoma.
    MacGregor AB; Falk RE; Landi S; Ambus U; Langer B
    Surg Gynecol Obstet; 1975 Nov; 141(5):747-54. PubMed ID: 1105837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrent malignant melanoma: effect of adjuvant immunotherapy on survival.
    McCulloch PB; Dent PB; Blajchman M; Muirhead WM; Price RA
    Can Med Assoc J; 1977 Jul; 117(1):33-6. PubMed ID: 861909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.